These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

244 related articles for article (PubMed ID: 29958030)

  • 1. Suppression of Th1-Mediated Keratoconjunctivitis Sicca by Lifitegrast.
    Guimaraes de Souza R; Yu Z; Stern ME; Pflugfelder SC; de Paiva CS
    J Ocul Pharmacol Ther; 2018 Sep; 34(7):543-549. PubMed ID: 29958030
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Sjögren's syndrome associated dry eye in a mouse model is ameliorated by topical application of integrin α4 antagonist GW559090.
    Contreras-Ruiz L; Mir FA; Turpie B; Krauss AH; Masli S
    Exp Eye Res; 2016 Feb; 143():1-8. PubMed ID: 26463157
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Lifitegrast Ophthalmic Solution 5% (Xiidra) for Dry Eye Disease.
    Patel J; Franko J
    Am Fam Physician; 2018 Jul; 98(2):119-120. PubMed ID: 30215991
    [No Abstract]   [Full Text] [Related]  

  • 4. Lifitegrast Ophthalmic Solution 5.0% versus Placebo for Treatment of Dry Eye Disease: Results of the Randomized Phase III OPUS-2 Study.
    Tauber J; Karpecki P; Latkany R; Luchs J; Martel J; Sall K; Raychaudhuri A; Smith V; Semba CP;
    Ophthalmology; 2015 Dec; 122(12):2423-31. PubMed ID: 26365210
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Lifitegrast ophthalmic solution 5.0% for treatment of dry eye disease: results of the OPUS-1 phase 3 study.
    Sheppard JD; Torkildsen GL; Lonsdale JD; D'Ambrosio FA; McLaurin EB; Eiferman RA; Kennedy KS; Semba CP;
    Ophthalmology; 2014 Feb; 121(2):475-83. PubMed ID: 24289915
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Efficacy of Trabodenoson in a Mouse Keratoconjunctivitis Sicca (KCS) Model for Dry-Eye Syndrome.
    Žiniauskaite A; Ragauskas S; Hakkarainen JJ; Rich CC; Baumgartner R; Kalesnykas G; Albers DS; Kaja S
    Invest Ophthalmol Vis Sci; 2018 Jun; 59(7):3088-3093. PubMed ID: 30025146
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Lifitegrast: First LFA-1/ICAM-1 antagonist for treatment of dry eye disease.
    Paton DM
    Drugs Today (Barc); 2016 Sep; 52(9):485-493. PubMed ID: 27883115
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Topical cyclosporine inhibits conjunctival epithelial apoptosis in experimental murine keratoconjunctivitis sicca.
    Strong B; Farley W; Stern ME; Pflugfelder SC
    Cornea; 2005 Jan; 24(1):80-5. PubMed ID: 15604871
    [TBL] [Abstract][Full Text] [Related]  

  • 9. RGN-259 (thymosin β4) improves clinically important dry eye efficacies in comparison with prescription drugs in a dry eye model.
    Kim CE; Kleinman HK; Sosne G; Ousler GW; Kim K; Kang S; Yang J
    Sci Rep; 2018 Jul; 8(1):10500. PubMed ID: 30002412
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Disruption of TGF-β signaling improves ocular surface epithelial disease in experimental autoimmune keratoconjunctivitis sicca.
    De Paiva CS; Volpe EA; Gandhi NB; Zhang X; Zheng X; Pitcher JD; Farley WJ; Stern ME; Niederkorn JY; Li DQ; Flavell RA; Pflugfelder SC
    PLoS One; 2011; 6(12):e29017. PubMed ID: 22194977
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Ocular Distribution and Pharmacokinetics of Lifitegrast in Pigmented Rabbits and Mass Balance in Beagle Dogs.
    Chung JK; Spencer E; Hunt M; McCauley T; Welty D
    J Ocul Pharmacol Ther; 2018; 34(1-2):224-232. PubMed ID: 29267138
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Desiccating stress-induced chemokine expression in the epithelium is dependent on upregulation of NKG2D/RAE-1 and release of IFN-γ in experimental dry eye.
    Coursey TG; Bohat R; Barbosa FL; Pflugfelder SC; de Paiva CS
    J Immunol; 2014 Nov; 193(10):5264-72. PubMed ID: 25288568
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Lifitegrast ophthalmic solution for treatment of ocular chronic graft-versus-host disease.
    Chhabra S; Jerkins JH; Conto JE; Zellner K; Shah NN; Hari PN; Hamadani M
    Leuk Lymphoma; 2020 Apr; 61(4):869-874. PubMed ID: 31762357
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Lifitegrast Ophthalmic Solution 5%: A Review in Dry Eye Disease.
    Keating GM
    Drugs; 2017 Feb; 77(2):201-208. PubMed ID: 28058622
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Topical interferon-gamma neutralization prevents conjunctival goblet cell loss in experimental murine dry eye.
    Zhang X; De Paiva CS; Su Z; Volpe EA; Li DQ; Pflugfelder SC
    Exp Eye Res; 2014 Jan; 118():117-24. PubMed ID: 24315969
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effect of cyclosporine on conjunctival mucin in a canine keratoconjunctivitis sicca model.
    Moore CP; McHugh JB; Thorne JG; Phillips TE
    Invest Ophthalmol Vis Sci; 2001 Mar; 42(3):653-9. PubMed ID: 11222523
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Ectoine Enhances Mucin Production Via Restoring IL-13/IFN-γ Balance in a Murine Dry Eye Model.
    Lin N; Chen X; Liu H; Gao N; Liu Z; Li J; Pflugfelder SC; Li DQ
    Invest Ophthalmol Vis Sci; 2024 Jun; 65(6):39. PubMed ID: 38935032
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Clinical Outcomes of Lifitegrast 5% Ophthalmic Solution in the Treatment of Dry Eye Disease.
    Tong AY; Passi SF; Gupta PK
    Eye Contact Lens; 2020 Jan; 46 Suppl 1():S20-S24. PubMed ID: 30985492
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Lifitegrast for the treatment of dry eye disease in adults.
    Donnenfeld ED; Perry HD; Nattis AS; Rosenberg ED
    Expert Opin Pharmacother; 2017 Oct; 18(14):1517-1524. PubMed ID: 28841079
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Immediate Effect of 3% Diquafosol Ophthalmic Solution on Tear MUC5AC Concentration and Corneal Wetting Ability in Normal and Experimental Keratoconjunctivitis Sicca Rat Models.
    Choi KE; Song JS; Kang B; Eom Y; Kim HM
    Curr Eye Res; 2017 May; 42(5):666-671. PubMed ID: 27791390
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.